University of Oxford Reports Findings in Falciparum Malaria (Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children).

A study conducted by the University of Oxford in Burkina Faso evaluated the safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in children aged 5-17 months. The trial showed that the vaccine had a favorable safety profile, was well tolerated, and demonstrated promising efficacy against clinical malaria, particularly when administered in a delayed third-dose regimen. The research, funded by various organizations, highlighted the potential of RH5.1/Matrix-M as a safe and highly immunogenic vaccine for African children, with ongoing monitoring of its efficacy. [Extracted from the article]